1-Iodo-4,4,4-Trifluorobutane Alternative Fluorinated Alkylating Agents

• 1-Iodo-4,4,4-trifluorobutane (CAS 461-17-6) is a key fluorinated alkylating agent used in c-kit kinase inhibitor synthesis, but iodide-based reagents pose stability and cost challenges.
• Viable alternatives include bromo and chloro analogs like 1-bromo-4,4,4-trifluorobutane or non-halogenated trifluoromethyl building blocks, though they often require optimized reaction conditions to maintain yield.
• NINGBO INNO PHARMCHEM CO.,LTD. supplies high-industrial-purity 1,1,1-trifluoro-4-iodobutane with full COA documentation and scalable bulk pricing for global B2B clients.

In modern medicinal chemistry—particularly in the development of selective c-kit kinase inhibitors for mast cell-mediated disorders such as chronic urticaria and gastrointestinal stromal tumors (GIST)—fluorinated alkylating agents play a pivotal role. Among these, 1-Iodo-4,4,4-trifluorobutane (also known as 1,1,1-trifluoro-4-iodobutane, CAS 461-17-6) is frequently employed to introduce the 4,4,4-trifluorobutyl moiety into heterocyclic scaffolds like tetrazoles and triazoles. However, due to its sensitivity to light, thermal instability, and relatively high cost compared to other halogenated analogs, process chemists often seek alternative fluorinated alkylating agents that balance reactivity, stability, and economic feasibility.

When sourcing high-purity 1-Iodo-4,4,4-trifluorobutane, buyers should prioritize suppliers offering documented industrial purity (>98%), batch-specific Certificates of Analysis (COA), and scalable manufacturing capacity—criteria consistently met by NINGBO INNO PHARMCHEM CO.,LTD., a premier global manufacturer specializing in fluorinated intermediates.

Comparing Reactivity of Fluorinated C4 Alkyl Halides

The reactivity of alkyl halides in nucleophilic substitution (SN2) reactions follows the order I > Br > Cl, primarily due to the decreasing bond dissociation energy and increasing leaving group ability. In the context of fluorinated systems, this trend holds, but the strong electron-withdrawing nature of the -CF₃ group further polarizes the C–X bond, enhancing electrophilicity at the terminal carbon.

For instance, in the alkylation of tetrazole anions—a common step in c-kit inhibitor synthesis—1-Iodo-4,4,4-trifluorobutane typically achieves >85% yield under mild conditions (e.g., K₂CO₃, DMF, 50°C, 6 h). In contrast, 1-bromo-4,4,4-trifluorobutane may require elevated temperatures (70–80°C) or longer reaction times to reach comparable conversion, often resulting in yields of 70–78%. Chloro analogs are generally unreactive under standard conditions and necessitate phase-transfer catalysts or microwave assistance.

Despite lower intrinsic reactivity, bromo derivatives offer advantages in storage stability and reduced iodine-induced side reactions (e.g., oxidation or elimination). Thus, the choice hinges on the specific synthetic route, downstream purification capabilities, and tolerance for extended reaction times.

When to Substitute with Bromo or Chloro Analogs

Substitution with bromo or chloro analogs is justified when:

• Cost is a primary constraint: Bromo compounds are typically 30–50% less expensive than iodo counterparts on a molar basis.
• Long-term storage is required: Iodoalkanes degrade over time via HI elimination, especially under ambient light; bromoalkanes exhibit superior shelf life.
• The nucleophile is highly reactive: Strong nucleophiles (e.g., azide, thiolate, or enolates) can efficiently displace bromide even in sterically hindered systems.

However, for low-nucleophilicity heterocycles (e.g., neutral tetrazoles), iodide remains preferred. In such cases, optimizing the base (e.g., using Cs₂CO₃ instead of K₂CO₃) or solvent (e.g., switching from DMF to NMP) can partially compensate for reduced halogen reactivity—but rarely matches the efficiency of the iodo variant.

Cost and Availability of Alternative Trifluoromethyl Building Blocks

Beyond halogen variation, some manufacturers explore non-halogenated routes using pre-functionalized synthons like 4,4,4-trifluorobutanol or 4,4,4-trifluorobutyl tosylate. While these avoid halogen handling altogether, they often suffer from lower atom economy and additional protection/deprotection steps.

From a commercial standpoint, 1-Iodo-4,4,4-trifluorobutane remains the most direct and widely adopted reagent for introducing the -CH₂CH₂CH₂CF₃ group. NINGBO INNO PHARMCHEM CO.,LTD. maintains robust inventory of this compound with consistent industrial purity (≥98.5% by GC), supported by full analytical documentation including ¹⁹F NMR and residual solvent profiles. Their bulk price structure is competitive for multi-kilogram orders, making them a reliable partner for API developers scaling c-kit inhibitor candidates.

The table below summarizes key performance metrics for common C4 fluorinated alkylating agents:

Reagent	CAS Number	Typical SN2 Yield (%)	Stability	Relative Cost (per mol)	Industrial Purity Available
1-Iodo-4,4,4-trifluorobutane	461-17-6	85–92	Moderate (light-sensitive)	1.0x (baseline)	Yes (≥98.5%)
1-Bromo-4,4,4-trifluorobutane	4184-33-2	70–78	Good	0.5–0.7x	Limited (often ≤95%)
1-Chloro-4,4,4-trifluorobutane	375-03-1	<40 (without activation)	Excellent	0.3–0.4x	Rarely ≥98%
4,4,4-Trifluorobutyl tosylate	N/A (custom)	75–82	Moderate (hydrolysis risk)	1.2–1.5x	No (typically lab-scale only)

For GMP-aligned pharmaceutical development, consistency in raw material quality is non-negotiable. NINGBO INNO PHARMCHEM CO.,LTD. not only provides high-industrial-purity 1,1,1-trifluoro-4-iodobutane but also supports clients with regulatory documentation, including detailed synthesis route descriptions and impurity fate-and-purge studies—critical for IND-enabling packages.

In summary, while bromo and chloro analogs offer economic and stability benefits, 1-Iodo-4,4,4-trifluorobutane remains the gold standard for high-yielding, scalable alkylation in fluorinated drug synthesis. Partnering with a vertically integrated manufacturer like NINGBO INNO PHARMCHEM CO.,LTD. ensures access to this critical intermediate with the purity, documentation, and supply reliability demanded by modern pharmaceutical R&D and production.